A new TR-FRET Assay Platform : THUNDER™

   
Time-Resolved FRET (or TR-FRET) is a well-established technology widely used in drug discovery and clinical diagnostics, and increasingly it has turned out to be a highly versatile assay technology, allowing the study of a wide range of biological interactions ranging from low to high affinity, using both small and large molecules. Join our upcoming webcast, presented by Bioauxilium on June 27, 2024 for exclusive insights on Introduction to BioAuxilium’s THUNDER™ TR-FRET Assay Platform with Jaime Padros, PhD, President, at our principle company BioAuxilium Research.Visit W3Schools.com!

Get the chance to learn about

  • Overview of the THUNDER™ TR-FRET assay platform
  • Advantages of THUNDER™ over traditional TR-FRET platforms
  • Phospho-protein detection in cell lysates with THUNDER
  • Biomarker detection in cell supernatants with THUNDER
  • THUNDER cAMP Assay Kit
  • BioAuxilium’s validation process
Document

Engage in thought-provoking discussions with our experts during the interactive Q&A session


Speaker Jaime Padros, PhD

President, BioAuxilium Research

Dr. Jaime Padros is the co-founder and President of BioAuxilium Research, a Canadian private biotech specialized in the design, development, and manufacturing of drug discovery assay kits and reagents based on the THUNDER™ TR-FRET technology. Jaime has 25 years of experience developing and optimizing biochemical and cell-based assays using diverse technologies for high-throughput screening applications.

Prior to BioAuxilium, Jaime led the design and development of a range of drug discovery assay kits and reagents at PerkinElmer Bio-discovery (now Revvity), including the commercially successful portfolio of LANCE® Ultra TR-FRET assays.

© 2022 - Krishgen Biosystems. All Rights Reserved | Privacy Policy